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Nowadays, tuberculosis (TB) remains a major cause of death among 
infectious diseases in post-soviet countries, including Ukraine. Despite certain 
positive changes, for example a reducing the TB incidence during the period 
2006-2011from 83.2 to 67.2 per 100 000 population [1,2], it is still a high level 
of multidrug-resistant tuberculosis, for example  primary resistance vary from 7 
to 25 %, which significantly reduces the effectiveness of treatment [3,4].  
It is known that the efficiency of treatment of numerous diseases, the 
severity of their course and their outcome largely depends on the genetic 
characteristics of a person, for example from the polymorphism of genes of 
xenobiotics detoxification [5,6]. Among the last there is an important gene of 
cytochrome P-450 2E1 (CYP2E1) - a putative enzyme that participate in 
metabolism of the most effective antituberculosis drug isoniazid  [6]. That is 
why the polymorphism of that gene may affect the concentration of isoniazid 
and consequently an effectiveness of TB treatment. In previous studies it was 
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shown that the polymorphism of N-acetyltransferase 2, which determine the 
concentration of isoniazid, has an influence on outcome of treatment in [7,8]. So 
the next step was to study the effectiveness of treatment of TB-patients 
considering CYP2E1 genotype.  
Aim of research: to detect the peculiarities of pulmonary TB course and 
outcome after in-patient treatment according to CYP2E1 genotype of the patients 
with primary TB. 
Materials and methods. An analysis of medical cards from 86 patients 
with primary pulmonary tuberculosis at the end of in-patient treatment in Odessa 
regional antituberculosal dispensary was conducted in 2012 year. Among 
enrolled patients 40 (46.5%) were women, others – 46 (53.5%) – were men. The 
age varied from 18 to 73 years (average – 35.9 years). All TB patients were 
receiving a standard therapy according to Order of Ministry of Healthcare № 
384 from 9.06.2006 that implemented principles of DOTS-strategy [10]. We 
have considered medical diagnosis at the beginning and at the end of in-patients 
treatment including TB-form, characteristics of TB-lesions, bacterial excretion 
etc.  
At the beginning of provided treatment it was detected a CYP2E1 
genotype in TB-patients. DNA material was extracted from the blood of donors 
using a DNA sorbB kit (AmpliSens, Russian Federation).  A CYP2E1 genotype 
was detected with the help of polymerase chain reaction (PCR) and 
endonuclease analysis [11,12]. It has been studied presence of mutation in intron 
6 and flanking ´5 region with the help of corresponding enzymes DraI and RsaI. 
Processing of obtained statistical data was performed using Microsoft Excel and 
«Primer Biostatistica» program. 
Results. According to CYP2Е1 genotype out of 86 patients 84 (97.7%) had 
no mutation in ´5-flanking region (с1/с1 genotype), others – 2 (2.3%) had one 
mutated allele (с1/с2 genotype). Concerning  intron 6 the majority of patients 74 
(86.0%) had no mutation in this region (СС genotype), 11 patients (12.8%) had 
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one mutated allele (CD genotype), 1 patient (1.2%) had both mutated alleles 
(DD genotype). Both patients with mutations in ´5-flanking region, also had a 
mutation in 6
th
 intron. Further for convenience we formed a group of patients 
without mutations in 6
th
 intron (СС genotype) and a group of patients that had 
mutation(s) in mentioned locus (CD, DD genotypes). After completion of in-
patient treatment in two patients with CD, DD genotype (16.7%) a diagnosis of 
TB was cancelled after the proving pulmonary cancer. In patients with СС 
genotype it was no cases of detected pulmonary cancer, thus,CD, DD genotype  
more often associated with pulmonary cancer development that СС genotype 
(Р<0.05; χ2=14,63 at a critical value here and after 3.84). In addition in every 
group it was proved one case of pneumonia that at the beginning was diagnosed 
as TB. So, in the end hospital stage treatment a diagnosis of pulmonary TB was 
supported in 73 patients with СС genotype and in 9 patients CD, DD genotype. 
The medical cards of patients with proved pulmonary TB were enrolled in 
further statistic processing. 
At the beginning of in-patient department treatment the destruction 
processes in lungs were observed approximately in two-third of the patients with 
CD, DD genotype and in 42.5% with CC genotype. Approximately 38.4% of the 
carriers of CC genotype and 44.4% of CD, DD genotype had bilateral 
pulmonary TB. Two-third of the patients in both groups had infiltrative TB, 
others – had disseminative and focal TB.  
Among the individuals with CC genotype the processes of disintegration 
and dissemination in lungs occurred in 23.3 and 13.7% respectively. At the same 
time among the patients with CD, DD genotype mentioned above processes 
were observed in 11.1% and 33.3% correspondently.  So, among the patients 
with CD, DD genotype the processes of dissemination were somewhat more 
frequent than in carriers of CC genotype.  
At the beginning of in-patient treatment regardless of genotype and 
according to the microscopy approximately half of patients with genotype СС 
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and one-third of individuals with genotype CD, DD were smear positive. 
According to the cultural method the majority of patients – 67.1% of CC 
genotype carriers and half of CD, DD genotype carriers were smear-positive. 
Also vast majority of the patients with genotype of CC and CD, DD belonged to 
I (primary pulmonary tuberculosis) – 72.6% and 77.8% respectively. Other 
patients belongs either to III category (smear-negative primary tuberculosis) – 
CC genotype or to II category CD, DD genotype. Thus, at the beginning of 
treatment there was no significant differences between TB-patients according to 
CYP2Е1 polymorphism, however the patients with genotype CD, DD had the 
manifestations of dissemination and destruction in pulmonary tissues somewhat 
more often than carriers of CC genotype.  
Duration of in-patient treatment was almost the same in both groups - 
93,1±8,0  days for patients with CC genotype and 96,2±3,4 days with CD, DD 
genotype.  
At the end of in-patient treatment the processes of destruction remained in 
20.5% of the patients with CC genotype and in 44.4% with CD, DD genotype.  
Termination of destruction was observed in half of the persons with CC 
genotype, in one-third of the CD, DD genotype carriers.  The longest conversion 
of destruction was in CD, DD patients – 59.7 days; somewhat faster it was CC 
carriers – 53.5 days.  
At the end as well as at the beginning of in-patient treatment in majority of 
the individuals with CC and CD, DD genotype (58.9% and 66.7%, respectively) 
an infiltrative form of a tuberculosis process was observed. The frequency of 
other TB forms also did not change during treatment.  
As a result of the conducted treatment the number of the CC genotype 
carriers with tuberculosis infiltration has decreased at 11.5 times (P<0.05 
χ2=53.66), while decreasing of TB-patients with infiltration among CD, DD 
genotype carriers was insignificant.  In addition at the time of completion of TB-
treatment the signs of pulmonary infiltration  among patients with CD, DD 
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genotype have been observed in 6 times more often than in patients with CC 
genotype (Р<0,05; χ2=7,96). In patients with СС genotype the number of 
patients with pulmonary destruction dropped in 2.4 times (Р<0,05; χ2=4,99), 
with signs of dissemination - in 9,8 times (Р<0,05; χ2=9,08). The symptoms of 
destruction and dissemination aborted in carriers with CD, DD genotype.  At the 
same time, the signs of resorption and consolidation in the pulmonary tissue 
were observed in 83.5% of the CC group and 66.7% of the CD, DD group.  
Regardless of genotype the percentage of patients with bi- and unilateral 
TB-lesions of the lungs, almost did not change during in-patient treatment. 
During conducted treatment the number of patients with genotype CC, which 
belonged to the 4 category (drug-resistant tuberculosis), rose up approximately 
in 16 times (P<0.05; χ2=14.98), with genotype CD, DD – on 22.2% (P>0.05). In 
the end of in-patient treatment in both groups around 22% of patients belong to 
4 category. Approximately  23.8% M.tuberculosis strains that were obtained 
from patients СС genotype, were multi-resistant (simultaneous resistance to 
isoniazid and rifampicin);  for patients with CD, DD genotype it was 25,0% of 
multi-resistant strains.  
According to the bacterioscopy all patients with CD, DD genotype, as well 
as 98.6% of the patients with CC genotype at the time of discharge from the 
hospital were smear-negative. In addition smear conversion has happened in 
97.3% individuals with CC genotype and 100% - with CD, DD genotype. It took 
56-62 days for the conversion of smear positive with no significant difference 
between two groups.  
According to the data of the culture method at the end of in-patient 
treatment 41.1% of the individuals with CC genotype as well as 28.6 of 
individuals with CD, DD genotype remained smear-positive. In the group with 
CC genotype number of smear-positive patients decreaed in 1.6 times (Р<0,05; 
χ2=9,96). Conversion of smear-positive into smear-negative have happened in 
38.8% of the patients with CC genotype and in half (2 out of 4) patients with 
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CD, DD genotype. In the same time the conversion of smear-positive patients 
took 67.1 days for CC genotype patients and 95.0 days for CD, DD genotype.  
Thus conversion of the patients with CD, DD genotype was in 1.4 times longer 
than in patients with CC genotype (Р<0,001; СІ=-40,36…-15,42).  
 The obtained data has proved that at the beginning of treatment there was 
no significant difference between TB patients concerning the signs of 
destruction, infiltration and disintegration according to CYP2E1 polymorphism, 
however the patients with CD, DD genotype more frequently had sings of 
dissemination and destruction in pulmonary tissues than the patients with CC 
genotype. 
At the end of in-patient treatment the processes of resorption and abortion 
of pulmonary infiltration more often associated with CC genotype, than with 
CD, DD genotype. It could be related with difference in metabolism of certain 
antituberculosis drugs by CYP2E1. In the same time differences in CYP2E1 
genotype almost had no effect on spreading of multiresistant M.tuberculosis 
strains. It will be interesting to check an influence of CYP2E1 polymorphism in 
TB-patients on toxicity of antituberculosis therapy. It will be important to check 
in coming researches an influence of CYP2E1 polymorphism in TB-patients on 
toxicity of antituberculosis therapy. 
Conclusion. 
1. At the beginning of treatment a polymorphism of CYP2Е1 in TB-patients 
almost has no influence on severity and forms of pulmonary tuberculosis.  
2. At the end of in-patient treatment the patients with CD, DD genotype 
more often exhibited signs of infiltration of pulmonary tissues and longer 
remained smear-positive according to cultural method, than the patients with CC 
genotype.  
3. Despite of CYP2E1 genotype around 25% of tuberculosis patients had 
multidrug resistant strains of M.tuberculosis in the end of in-patient treatment. 
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Summary. The polymorphism of the gene of cytochrome P-450 2E1 (CYP2E1) that participate in metabolism of 
antituberculosis agent isoniazid may influence on effectiveness of tuberculosis (TB) treatment.  
Aim of research: to detect the peculiarities of pulmonary TB course and outcome after in-patient 
treatment according to CYP2E1 genotype of the patients with primary TB. 
Materials and methods: analysis of medical cards from 86 patients with primary pulmonary tuberculosis 
at the end of hospital treatment in Odessa regional antituberculosal dispensary was conducted in 2012 year with 
consideration of CYP2E1 genotype. 
Results: the obtained data has proved that at the beginning of treatment there was no significant 
difference between TB patients concerning the signs of destruction, infiltration and disintegration according to 
CYP2E1 polymorphism, however the patients with CD, DD genotype more frequently had sings of 
dissemination and destruction in pulmonary tissues than the patients with CC genotype. At the end of in-patient 
treatment the patients with CD, DD genotype more often exhibited signs of infiltration of pulmonary tissues and 
longer remained smear-positive according to cultural method, than the patients with CC genotype. Despite of 
CYP2E1 genotype around 25% of tuberculosis patients had multidrug resistant strains of M.tuberculosis in the 
end of in-patient treatment. It will be important to check in coming researches an influence of CYP2E1 
polymorphism in TB-patients on toxicity of antituberculosis therapy. 
Key words: tuberculosis, CYP2E1, treatment outcome 
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Table 1 
The characteristics of TB-processes according to CYP2E1 genotype  
The characteristics of 
TB-processes 
At the beginning of 
treatment, (%) 
At the end of in-patient 
treatment, (%) 
CC,  
n=73 
CC, CD, 
n=12 
CC,  
n=73 
CC, CD, 
n=12 
Spreading bi-
lateral 
28 (38,4) 4 (44,4) 27 (37,0) 4 (44,4) 
unila-
teral 
45 (61,6) 5 (55,6) 46 (63,0) 5 (55,6) 
Destruction yes 31 (42,5) 6 (66,7) 15 (20,5)
 
4 (44,4) 
no 42 (57,5) 3 (33,3) 58 (79,5) 5 (55,6) 
Stage of 
TB-process 
infil-
tration 
46 (63,0) 5 (55,6) 4 (5,5)#
 
3 (33,3)* 
disinteg
ration 
17 (23,3) 1 (11,1) 7 (9,6)# - 
dissemi
nation 
10 (13,7) 3 (33,3) 1 (1,4)# - 
resorp-
tion 
- - 61 (83,5) 6 (66,7) 
Category 
of patients 
1 53 (72,6) 7 (77,8) 46 (62,7) 6 (66,7) 
2 4 (5,5) 2 (22,2) 3 (4,5) 1 (11,1) 
3 15 (20,5) - 8 (10,4) - 
4 1 (1,4) - 16 (22,4)
 
2 (22,2) 
Footnote: # - Р<0.05 (relatively to the initial level of the correspondent group);  
        * - Р<0.05 (relatively to the patients with CC genotype) 
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Table 2 
Conversion of destruction and smear positive depending on CYP2E1 genotype  
Group 
of 
patients 
Conversion of 
destruction 
Conversion of smear positive according to 
bacterioscopy culture 
number 
of 
patients 
(%) 
duration  
(days) ± 
SEM 
number 
of 
patients 
(%) 
duration  
(days) ± 
SEM 
number 
of 
patients 
(%) 
duration  
(days) ± 
SEM 
CC 16/31 
(51,6) 
53,50±1,41 36/37 
(97,3) 
56,83±1,80 19/49 
(38,8) 
67,11±1,21 
 
CC, 
CD 
2/6 
(33,3) 
59,71±1,87 4/4 
(100) 
62,00±1,05 2/4 
(50,0) 
95,00±15,56* 
Footnote: * - Р<0.05 (relatively to the patients with CC genotype) 
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infiltrative disseminative focal
 
Fig. 1 Forms of pulmonary TB taken into consideration CYP2E1 genotype at the 
beginning (before) and at the end (after) of in-patient treatment   
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Fig. 2 Number of the patients with different CYP2E1 genotype that were smear 
positive according to bacterioscopy (B+) or culture method (C+) at the 
beginning (before) and at the end (after) in-patient treatment 
Footnote: *-Р<0.05 relatively to the initial level of the correspondent group  
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